This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Past Earnings Performance

Past criteria checks 0/6

Atreca's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 15.5% annually.

Key information

-14.6%

Earnings growth rate

51.1%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-908.6%
Net Margin	n/a
Last Earnings Update	30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Atreca makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:BCEL Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Sep 23	-98	36	45
30 Jun 23	-85	38	51
31 Mar 23	-93	39	58
31 Dec 22	-97	39	62
30 Sep 22	-105	40	68
30 Jun 22	-110	41	70
31 Mar 22	-108	43	67
31 Dec 21	-109	43	67
30 Sep 21	-103	42	61
30 Jun 21	-98	42	59
31 Mar 21	-92	38	55
31 Dec 20	-86	37	52
30 Sep 20	-83	37	50
30 Jun 20	-76	33	48
31 Mar 20	-74	29	50
31 Dec 19	-67	24	49
30 Sep 19	-59	17	48
30 Jun 19	-53	13	43
31 Mar 19	-44	11	35
31 Dec 18	-38	9	31

Quality Earnings: BCEL is currently unprofitable.

Growing Profit Margin: BCEL is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BCEL is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).

Return on Equity

High ROE: BCEL has a negative Return on Equity (-908.6%), as it is currently unprofitable.

This company listing is no longer active

Atreca Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies